Get started
Author

Ahmed M. Abdelhady

Observed names: A. Abdelhady, A. M. Abdelhady, A.M. Abdelhady, Ahmed Abdelhady, Ahmed M Abdelhady
Observed institutions: Goethe University Frankfurt, Centre National de la Recherche Scientifique, The University of Sydney, University of Auckland, Inserm, Université de Lille, University of Cambridge, Auckland City Hospital, Cambridge University Hospitals NHS Foundation Trust, Humboldt-Universität zu Berlin, Novartis (India), Novartis (United States), Intellia Therapeutics (United States), University Hospital Frankfurt, Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, University of Amsterdam, Université Grenoble Alpes
ORCID: 0000-0001-9404-5397
Observed ORCID: 0000-0001-9404-5397
OpenAlex ID: A5102018126
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
2024 · Hilary J. Longhurst, Karen Lindsay, et al. · New England Journal of Medicine · 200
CRISPR-Based Therapy for Hereditary Angioedema
2024 · Danny M. Cohn, Padmalal Gurugama, et al. · New England Journal of Medicine · 84
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
2020 · Sara M. Tolaney, Young-Hyuck Im, et al. · Clinical Cancer Research · 41
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin‐Dependent Kinase 4/6 Inhibitor, in Healthy Subjects
2020 · Yan Ji, Ahmed M. Abdelhady, et al. · Clinical Pharmacology in Drug Development · 21
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2019 · Ulrich Jaeger, Nina Worel, et al. · Blood · 21
Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
2021 · Stephen J. Schuster, Michael J. Dickinson, et al. · Journal of Clinical Oncology · 17
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
2022 · Armando Santoro, Wu-Chou Su, et al. · Lung Cancer · 15
PDF
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
2026 · Danny M. Cohn, Padmalal Gurugama, et al. · New England Journal of Medicine · 14
Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
2021 · Ulrich Jäger, Nina Worel, et al. · Journal of Clinical Oncology · 10
Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies
2023 · Ahmed M. Abdelhady, Jonathan A. Phillips, et al. · Clinical Pharmacology & Therapeutics · 8
PDF
Efficacy and Safety of Tisagenlecleucel (tisa‐cel) in Adult Patients (pts) With Relapsed/refractory Follicular Lymphoma (r/r Fl): Primary Analysis of the Phase 2 Elara Trial
2021 · S. J. Schuster, M. Dickinson, et al. · Hematological Oncology · 7
PDF
561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours
2020 · P. LoRusso, M. Fakih, et al. · Annals of Oncology · 6
Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
2018 · A. Santoro, W.-C. Su, et al. · Annals of Oncology · 5
Safety and Efficacy of Tisagenlecleucel Plus Pembrolizumab in Patients With Relapsed/refractory Diffuse Large B‐cell Lymphoma: Updated Analysis of the Phase 1b Portia Study
2021 · U. Jaeger, N. Worel, et al. · Hematological Oncology · 1
PDF
Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)
2020 · Ulrich Jaeger, Nina Worel, et al. · Cancer Research · 1
Supplementary Data from Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
2023 · Sara M. Tolaney, Young-Hyuck Im, et al.
Supplementary Data from Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
2023 · Sara M. Tolaney, Young-Hyuck Im, et al.
PDF
Data from Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
2023 · Sara M. Tolaney, Young-Hyuck Im, et al.
Data from Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
2023 · Sara M. Tolaney, Young-Hyuck Im, et al.
Works count: 19
Citation count: 451
H-index: 9
I10-index: 9
Year
Topic
Type